Vanguard Group Inc. Grows Stock Holdings in Phreesia, Inc. $PHR

Key Points

• Vanguard Group Inc. increased its stake in Phreesia, Inc. by 2.4%, owning approximately 8.40% of the company, valued at $126.2 million.
• A majority of Phreesia's stock, 92.10%, is owned by institutional investors and hedge funds, indicating strong institutional interest in the company.
• Analyst ratings on Phreesia are positive, with KeyCorp raising its price target to $35.00 and a consensus rating of "Buy" from multiple analysts.

Vanguard Group Inc. lifted its position in Phreesia, Inc. (NYSE:PHR - Free Report) by 2.4% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 4,936,515 shares of the company's stock after purchasing an additional 113,405 shares during the period. Vanguard Group Inc. owned about 8.40% of Phreesia worth $126,177,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also recently modified their holdings of PHR. Johnson Financial Group Inc. boosted its holdings in Phreesia by 381.3% in the 4th quarter. Johnson Financial Group Inc. now owns 1,131 shares of the company's stock worth $28,000 after buying an additional 896 shares during the period. Quarry LP lifted its position in shares of Phreesia by 210.9% in the fourth quarter. Quarry LP now owns 2,835 shares of the company's stock valued at $71,000 after acquiring an additional 1,923 shares in the last quarter. KBC Group NV purchased a new position in shares of Phreesia in the first quarter valued at about $74,000. CWM LLC boosted its stake in shares of Phreesia by 994.9% in the first quarter. CWM LLC now owns 4,040 shares of the company's stock worth $103,000 after acquiring an additional 3,671 shares during the period. Finally, NewEdge Advisors LLC grew its position in shares of Phreesia by 12.1% during the fourth quarter. NewEdge Advisors LLC now owns 4,256 shares of the company's stock worth $107,000 after purchasing an additional 459 shares in the last quarter. 92.10% of the stock is currently owned by institutional investors.

Phreesia Price Performance

Shares of NYSE PHR traded up $0.61 during midday trading on Monday, reaching $30.36. 1,047,812 shares of the stock traded hands, compared to its average volume of 523,506. The company's 50 day moving average is $27.49 and its 200 day moving average is $26.39. Phreesia, Inc. has a one year low of $17.07 and a one year high of $31.04. The company has a debt-to-equity ratio of 0.02, a current ratio of 1.95 and a quick ratio of 1.95. The stock has a market capitalization of $1.81 billion, a PE ratio of -41.03 and a beta of 0.71.

Phreesia (NYSE:PHR - Get Free Report) last released its quarterly earnings results on Wednesday, May 28th. The company reported ($0.07) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.13) by $0.06. Phreesia had a negative net margin of 9.83% and a negative return on equity of 16.23%. The company had revenue of $115.94 million for the quarter, compared to the consensus estimate of $115.00 million. During the same quarter in the prior year, the firm earned ($0.05) earnings per share. Phreesia's revenue was up 14.5% on a year-over-year basis. Phreesia has set its FY 2026 guidance at EPS. On average, equities research analysts anticipate that Phreesia, Inc. will post -1.1 earnings per share for the current year.

Wall Street Analysts Forecast Growth

PHR has been the topic of several recent analyst reports. Citigroup reissued a "buy" rating on shares of Phreesia in a research note on Wednesday, May 28th. Canaccord Genuity Group cut their price objective on shares of Phreesia from $35.00 to $34.00 and set a "buy" rating for the company in a report on Thursday, May 29th. Truist Financial lifted their price objective on shares of Phreesia from $34.00 to $35.00 and gave the company a "buy" rating in a research report on Thursday, May 29th. Wall Street Zen raised shares of Phreesia from a "hold" rating to a "buy" rating in a report on Sunday, June 1st. Finally, KeyCorp raised their target price on shares of Phreesia from $28.00 to $35.00 and gave the company an "overweight" rating in a research note on Monday, July 14th. One research analyst has rated the stock with a Strong Buy rating and ten have assigned a Buy rating to the company's stock. According to data from MarketBeat.com, Phreesia has a consensus rating of "Buy" and a consensus price target of $32.27.

Insider Activity at Phreesia

In other Phreesia news, Director Michael Weintraub sold 7,431 shares of the business's stock in a transaction that occurred on Monday, June 9th. The stock was sold at an average price of $27.51, for a total transaction of $204,426.81. Following the completion of the transaction, the director owned 143,039 shares in the company, valued at $3,935,002.89. The trade was a 4.94% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Lisa Egbuonu-Davis sold 2,802 shares of Phreesia stock in a transaction on Thursday, June 26th. The stock was sold at an average price of $27.67, for a total value of $77,531.34. Following the sale, the director owned 22,037 shares of the company's stock, valued at approximately $609,763.79. This trade represents a 11.28% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 53,882 shares of company stock valued at $1,513,007 over the last three months. Corporate insiders own 5.50% of the company's stock.

Phreesia Profile

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.